FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2

Oncotarget

Volumn 5, Issue 13, 2014, Pages 5113-5124

  Liu, Li Li ^a   Lu, Shi Xun ^a   Li, Min ^a   Li, Lin Zi ^a   Fu, Jia ^a   Hu, Wen ^a   Yang, Yuan Zhong ^a   Luo, Rong Zhen ^a   Zhang, Chris Zhiyi ^a   Yun, Jing Ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

AKT2; FoxD3; HCC; Metastasis; miR 137

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 137; PROTEIN FOXD3; PROTEIN KINASE B BETA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; AKT2 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXD3 PROTEIN, HUMAN; MIRN137 MICRORNA, HUMAN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN RNA BINDING; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TUMOR GROWTH; 3' UNTRANSLATED REGION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR VOLUME; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905036620     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2089     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90.
2. Forner A, Hessheimer AJ, Isabel Real M and Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 2006; 60(2):89-98.
3. El-Serag HB and Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-2576.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
5. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. The New England journal of medicine. 2005; 353(17):1768-1771.
6. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ and Qin LX. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 2013; 58(1):158-170.
7. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y and Sun S. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology. 2010; 51(5):1614-1623.
8. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW and Taioli E. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer. 2011; 117(7):1454-1462.
9. Liang L, Li X, Zhang X, Lv Z, He G, Zhao W, Ren X, Li Y, Bian X, Liao W, Liu W, Yang G and Ding Y. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2. Gastroenterology. 2013; 144(3):624-635 e624.
10. Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-1274.
11. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, Matsuura N and Monden M. Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncology reports. 2004; 11(1):25-32.
12. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY and Slamon DJ. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer research. 2003; 63(1):196-206.
13. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E and Greco M. Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell death and differentiation. 2009; 16(4):571-583.
14. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y and Dahiya R. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer research. 2012; 72(14):3618-3630.
15. Li J, Chen Y, Zhao J, Kong F and Zhang Y. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer letters. 2011; 304(1):52-59.
16. Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, Yi C, Fu J, Hu W, Wen JM and Yun JP. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene. 2014.
17. Iorio MV and Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-5856.
18. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011; 140(5):1618-1628 e1616.
19. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PloS one. 2011; 6(1):e16435.
20. Filipowicz M. Prognostic potential of hepatic miR-122 measurements and antisense strategies targeting miR-122 as a therapeutic approach in viral hepatitis. Liver international: official journal of the International Association for the Study of the Liver. 2011; 31(4):437-439.
21. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K and Ng IO. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011; 140(1):322-331.
22. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
23. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, Diederichs S and Eichmuller SB. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. The Journal of investigative dermatology. 2013; 133(3):768-775.
24. Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, Li YH, Kang TB and Xu RH. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 2013; 34(4):803-811.
25. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, Wang L, Zhou J, Ren ZG, Li YX, Fan J and Wu WZ. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. The Journal of experimental medicine. 2013; 210(4):789-803.
26. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG, Ryan J, O'Meara A, O'Sullivan M and Stallings RL. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Molecular cancer. 2010; 9:83.
27. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A and Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular cell. 2007; 26(5):745-752.
28. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-843.
29. Liu Y, Mei C, Sun L, Li X, Liu M, Wang L, Li Z, Yin P, Zhao C, Shi Y, Qiu S, Fan J and Zha X. The PI3K-Akt pathway regulates calpain 6 expression, proliferation, and apoptosis. Cellular signalling. 2011; 23(5):827-836.
30. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999; 401(6748):82-85.
31. Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, Zhou X, Zeng Z, Li T, Yang Y and Hoffman AR. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res. 2003; 9(7):2719-2726.